Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KYMR
stocks logo

KYMR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
14.63M
+97.82%
-0.803
-9.8%
10.56M
-52.24%
-0.984
+19.95%
10.59M
-7.7%
-1.028
+8.26%
Estimates Revision
The market is revising Downward the revenue expectations for Kymera Therapeutics, Inc. (KYMR) for FY2025, with the revenue forecasts being adjusted by -32.9% over the past three months. During the same period, the stock price has changed by 52.22%.
Revenue Estimates for FY2025
Revise Downward
down Image
-32.9%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.31%
In Past 3 Month
Stock Price
Go Up
up Image
+52.22%
In Past 3 Month
Wall Street analysts forecast KYMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYMR is 73.22 USD with a low forecast of 53.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast KYMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYMR is 73.22 USD with a low forecast of 53.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 66.230
sliders
Low
53.00
Averages
73.22
High
90.00
Current: 66.230
sliders
Low
53.00
Averages
73.22
High
90.00
Truist
Buy
maintain
$68 -> $80
2025-11-26
Reason
Truist
Price Target
$68 -> $80
2025-11-26
maintain
Buy
Reason
Truist raised the firm's price target on Kymera Therapeutics to $80 from $68 and keeps a Buy rating on the shares. The firm is positive on the company's conviction in KT-621 potential, the Phase 2b initiation/dosing an additional indication, and the robust degradation and favorable safety profile seen in the Phase 1 study, the analyst tells investors in a research note. Truist adds that its key opinion leader checks indicate continued enthusiasm for KT-621 from a mechanistic perspective and give the firm confidence in clinical translation.
UBS
Buy
maintain
$70 -> $90
2025-11-26
Reason
UBS
Price Target
$70 -> $90
2025-11-26
maintain
Buy
Reason
UBS raised the firm's price target on Kymera Therapeutics to $90 from $70 and keeps a Buy rating on the shares. The firm previews December Phase 1b data for KT-621 in atopic dermatitis, expecting strong biomarker and early clinical responses similar to dupilumab along with clean safety, the analyst tells investors in a research note.
Barclays
NULL -> Overweight
maintain
$60 -> $70
2025-11-05
Reason
Barclays
Price Target
$60 -> $70
2025-11-05
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Kymera Therapeutics to $70 from $60 and keeps an Overweight rating on the shares following the Q3 report. The firm cites increased optimism for KT-621 for the target bump.
H.C. Wainwright
Buy
maintain
$70 -> $84
2025-11-05
Reason
H.C. Wainwright
Price Target
$70 -> $84
2025-11-05
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Kymera Therapeutics to $84 from $70 and keeps a Buy rating on the shares. The firm remains "encouraged" on Kymera's upcoming BroADen Phase 1b readout, saying it represents the first patient-level test of KT-621's ability to replicate dupilumab-like pathway control in an oral format.
Jefferies
Buy
maintain
$64 -> $73
2025-11-04
Reason
Jefferies
Price Target
$64 -> $73
2025-11-04
maintain
Buy
Reason
Jefferies raised the firm's price target on Kymera Therapeutics to $73 from $64 and keeps a Buy rating on the shares, calling out KT-621 atopic dermatitis data in December as a "key upcoming catalyst." The firm thinks the stock's momentum could continue if KT-621 further shows "oral Dupixent" potential, the analyst tells investors.
Morgan Stanley
Overweight
maintain
$70 -> $73
2025-11-04
Reason
Morgan Stanley
Price Target
$70 -> $73
2025-11-04
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Kymera Therapeutics to $73 from $70 and keeps an Overweight rating on the shares. Much of the attention on Kymera's Q3 earnings call was centered around the upcoming Phase 1b atopic dermatitis readout expected in December, notes the analyst, who says Kymera reiterated confidence in KT-621.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Kymera Therapeutics Inc (KYMR.O) is -17.49, compared to its 5-year average forward P/E of -16.77. For a more detailed relative valuation and DCF analysis to assess Kymera Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-16.77
Current PE
-17.49
Overvalued PE
-0.90
Undervalued PE
-32.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-14.56
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.05
Undervalued EV/EBITDA
-31.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
35.16
Current PS
0.00
Overvalued PS
53.10
Undervalued PS
17.22
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

KYMR News & Events

Events Timeline

(ET)
2025-11-25
07:02:59
Kymera Therapeutics reports dosing of first patient in BROADEN2 Phase 2b trial
select
2025-11-04 (ET)
2025-11-04
07:15:50
Kymera Therapeutics projects funding to last through the second half of 2028.
select
2025-11-04
07:15:24
Kymera Therapeutics Announces Q3 Earnings Per Share of 94 Cents, Exceeding Consensus Estimate of 79 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-28NASDAQ.COM
Kymera (KYMR) Q3 2025 Earnings Call Summary
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
2.0
11-26NASDAQ.COM
Kymera Approaches 52-Week Peak: Should Investors Buy, Sell, or Hold?

  • Stock Performance: Kymera Therapeutics, Inc. (KYMR) shares reached a 52-week high of $68.8, currently trading at $66.04, driven by optimism surrounding its lead candidate KT-621, which has surged 64.1% year-to-date compared to the industry’s 17.7% gain.

  • Pipeline Developments: KT-621, a first-in-class oral degrader for treating type 2 inflammation, is undergoing phase IIb trials for atopic dermatitis, with data expected by mid-2027. The company is also advancing a CDK2 molecular glue program in collaboration with Gilead Sciences.

  • Valuation Concerns: Despite promising developments, KYMR is considered overvalued with a price/book ratio of 4.99X, higher than the industry average. The consensus estimate for losses has widened for 2025 while narrowing for 2026.

  • Investment Recommendations: Current investors are advised to hold their shares, while potential investors should wait for a better entry point, especially given the recent changes in Sanofi's development strategy that may delay milestone payments for Kymera.

[object Object]
Preview
6.0
11-06Benzinga
Barclays Keeps Overweight Rating on Kymera Therapeutics and Increases Price Target to $70

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Kymera Therapeutics Inc (KYMR) stock price today?

The current price of KYMR is 66.23 USD — it has increased 0.36 % in the last trading day.

arrow icon

What is Kymera Therapeutics Inc (KYMR)'s business?

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.

arrow icon

What is the price predicton of KYMR Stock?

Wall Street analysts forecast KYMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYMR is 73.22 USD with a low forecast of 53.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Kymera Therapeutics Inc (KYMR)'s revenue for the last quarter?

Kymera Therapeutics Inc revenue for the last quarter amounts to 2.76M USD, decreased -26.12 % YoY.

arrow icon

What is Kymera Therapeutics Inc (KYMR)'s earnings per share (EPS) for the last quarter?

Kymera Therapeutics Inc. EPS for the last quarter amounts to -0.94 USD, increased 14.63 % YoY.

arrow icon

What changes have occurred in the market's expectations for Kymera Therapeutics Inc (KYMR)'s fundamentals?

The market is revising Downward the revenue expectations for Kymera Therapeutics, Inc. (KYMR) for FY2025, with the revenue forecasts being adjusted by -32.9% over the past three months. During the same period, the stock price has changed by 52.22%.
arrow icon

How many employees does Kymera Therapeutics Inc (KYMR). have?

Kymera Therapeutics Inc (KYMR) has 188 emplpoyees as of December 05 2025.

arrow icon

What is Kymera Therapeutics Inc (KYMR) market cap?

Today KYMR has the market capitalization of 4.77B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free